Inhaled corticosteroids (ICSs) improve asthma disease control; once-daily ICS administration may have advantages for patients. Our objective was to assess the efficacy and safety of the novel ICS fluticasone furoate (FF) over 24 weeks versus placebo.
Introduction
Inhaled corticosteroids (ICS) are the cornerstone of therapy for all severities of persistent asthma, with benefits including control of asthma symptoms, improvements in lung function and a decrease in airway hyperresponsiveness [1] . However, there continues to be potential to improve disease control in adults and children, especially from the perspective of adherence which, when low, can contribute to poor asthma control [1e3] .
Fluticasone furoate (FF) is a novel ICS in development for once-daily (OD) use in asthma. Structurally, FF is distinct from the twice-daily (BD) ICS, fluticasone propionate (FP) [4] . Preclinically, FF exhibits a greater antiinflammatory activity than FP [5, 6] . Clinically, FF, administered once-daily in the evening is non-inferior to the same daily dose administered twice daily with respect to lung function [7] ; exhibits significant effects versus placebo with respect to lung function over a range of doses and asthma severities [8e10]; has shown a significant effect on the allergen-induced early asthmatic response 23e24 h after dosing [11] ; and is indicated as a once-daily therapy for allergic rhinitis [12, 13] .
Dose-ranging studies of FF performed over 8 weeks have shown that the 100 mg dose provides a significant benefit in asthma [8, 9] , and exhibits similar lung function effects to FP250 mg BD in patients uncontrolled by low-dose ICS alone [9] . The present study sought to determine further whether this dose of FF (hereafter referred to as FF100 mg OD), given once-daily in the evening, is effective and tolerable over a longer period in patients with asthma uncontrolled by their current ICS. The primary endpoint was the effect of FF100 mg OD on lung function measured approximately 24-h post-dose at Week 24; secondary endpoints included symptomatic assessments of asthma, and safety was also assessed. The study was placebo-controlled and included FP250 mg BD as a reference arm for internal validation of results; it was not designed to assess non-inferiority or equivalence of FF100 mg OD to FP250 mg BD. Some of the results from this study have been presented in abstract form [14] .
Methods Patients
Patients were required to be !12 years of age with a diagnosis of asthma [15] for !12 weeks and maintained on a stable dose of ICS for !4 weeks prior to the screening visit. A pre-bronchodilator forced expiratory volume in 1s (FEV 1 ) of 40e90% predicted, adjusted for ethnicity [16] , and evening reversibility of !12% and !200 ml following albuterol/salbutamol inhalation were also required. Patients were required to be current non-smokers (!3 months) with a smoking history of less than 10 pack-years. Long-acting beta 2 agonists were not permitted within 4 weeks of the screening visit. The study was approved by local ethics review committees and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent from each adult (!18 years) patient was obtained prior to performing any studyspecific procedures, as was assent and written parental consent for each adolescent (12e17 years) patient.
Study design
This was a 24-week, randomised, multicentre, placebo-and active-controlled, double-blind, double-dummy, parallelgroup study (GSK study FFA112059; ClinicalTrials.gov NCT01159912) conducted at 56 centres in five countries between 30 June 2010 and 16 January 2012. Eligible patients entered a 4-week run-in period during which they were maintained on their stable dose of ICS (long-acting beta 2 agonists were not permitted), switched their rescue short-acting beta 2 agonist (SABA) to albuterol/salbutamol, and recorded symptoms, rescue use and morning/evening peak expiratory flow (PEF) in an electronic daily diary. Patients were eligible for randomisation if at the end of the 4-week run-in period they were (i) uncontrolled on their stable dose of run-in ICS medication, i.e. exhibited an evening pre-dose FEV 1 40e90% of predicted and reported an asthma symptoms score of !1 and/or rescue use on 4 of the last 7 days of the run-in period; and (ii) compliant with baseline medication and daily diary completion on 4 of the last 7 days of the run-in period.
The central randomisation schedule was generated by the sponsor using a validated computerised system (RandAll). Subjects were randomised using the Registration and Medication Ordering System (RAMOS), which was used by the study investigators or their designees to register and randomise the patients and receive their medication assignment information. Patients were randomised 1:1:1 to receive placebo, FF100 mg OD or FP250 mg BD. FF100 mg OD was administered in the evening (5 pme11 pm) via the ELLIPTAä dry powder inhaler (DPI) (representing an emitted dose of 92 mg) (ELLIPTAä is a trademark of the GlaxoSmithKline group of companies). Evening dosing for FF was employed based on prior studies which indicated oncedaily evening dosing is as efficacious as the same daily dose given twice daily, compared to once-daily morning dosing where a numerical advantage was observed with the same daily dose given twice daily [17] . FP250 mg BD was administered in the morning and evening via the DISKUSä/ ACCUHALERä device. Placebo was administered once-daily in the evening via the ELLIPTA DPI or twice daily via the DISKUS/ACCUHALER as appropriate. To maintain the study blind each patient received an ELLIPTA DPI (from which they inhaled once-daily in the evening) and a DISKUS/ ACCUHALER (from which they inhaled twice daily). Study visits took place at Weeks 2, 4, 8, 12, 16, 20 and 24; followup contact was conducted up to 1 week after completing study medication.
Assessments
The primary endpoint was mean change from baseline in pre-dose evening FEV 1 at 24 weeks. FEV 1 was measured electronically by spirometry at 5e11 pm using standard techniques. The mean change from baseline in the percentage of rescue-free 24-h periods over the 24 weeks of the study was a powered secondary endpoint. Additional secondary endpoints comprised mean change over the study period from baseline in evening/morning PEF and percentage of symptom-free 24-h periods. Change from baseline in the Asthma Quality of Life Questionnaire for 12 years and older (AQLQþ12; Qoltech, Bosham, UK) score at weeks 12 and 24 was also a secondary endpoint. Other endpoints were the change from baseline in the Asthma Control Testä (ACT: QualityMetric, Inc. Lincoln, RI, USA) score at weeks 12 and 24, and withdrawal due to lack of efficacy. The AQLQþ12 and ACT were administered at baseline and Study Visits 6 and 9 (Weeks 12 and 24).
Safety endpoints comprised the incidence of adverse events (AEs) and serious AEs (SAEs). Asthma exacerbations, defined as the need for oral or systemic corticosteroids for !3 days, or any hospitalisation requiring oral or systemic corticosteroids, and worsening of asthma, defined as the need for treatment additional to study medication and rescue medication were also assessed (but not specified as safety endpoints); as was pneumonia (confirmed by chest Xray) and oral/oropharyngeal candidiasis (assessed by oropharyngeal examination at each study visit and recorded as an AE if present). Standard laboratory parameters (haematology, clinical chemistry) and vital signs were assessed at baseline, 24 h-urine cortisol (UC) excretion was assessed at baseline and study end.
Statistical analysis
The primary comparison of interest was the difference between FF100 mg OD and placebo, while FP250 mg BD was also compared to placebo. The primary endpoint was pre-dose evening FEV 1 at Week 24 using last observation carried forward. This was assessed by analysis of covariance. The majority of the powered secondary, secondary and other endpoint comparisons were analysed using the same approach. AQLQþ12 and ACT were analysed using a repeated measures model and withdrawals due to lack of efficacy were analysed using Fisher's Exact test. To account for multiplicity across key endpoints a step-down closed testing procedure was employed (see additional methods in Online Supplementary Material). No formal analysis of differences between FF100 mg OD and FP250 mg BD was planned prior to the study; however the relative effects of FF100 mg OD and FP250 mg BD could be assessed by comparison of point estimates for FF100 mg OD versus placebo comparisons, and whether they lay within the 95% confidence interval for point estimates of FP250 mg BD versus placebo comparisons.
Additional detailed methods are provided in the Online Supplementary Material.
Results

Study population
Of 1036 patients screened, 349 were randomised, resulting in an intention-to-treat (ITT) population of 343, of whom 255 completed the study (Fig. 1) . The most common reason for early withdrawal was lack of efficacy which included asthma exacerbations, most of which occurred in the placebo group. Demographic and patient baseline characteristics are shown in Table 1 . The majority of study patients were white (79%) or of African heritage/AfricaneAmerican (19%), the mean (standard deviation [SD]) duration of asthma was 18.28 (14.006) years. ICSs most frequently used during prior to screening and during run-in were FP (42e48%) or budesonide (26e29%).
Efficacy Primary endpoint
Pre-dose evening FEV 1 was significantly improved at Week 24 relative to placebo by both FF100 mg OD and FP250 mg BD; both active treatments resulted in similar effects compared with placebo (Table 2) . Results for the PP population replicated those for the ITT population (Online Supplementary Material, Table 1 ). Over the study a small increase in pre-dose evening FEV 1 was observed in the placebo-treated group but both FF100 mg OD and FP250 mg BD caused greater effects ( 
Powered and other secondary endpoints
The percentage of rescue-free 24-h periods was significantly increased compared with placebo for both FF100 mg OD and FP250 mg BD (Table 2 ). In a post-hoc sensitivity analysis no difference from placebo was observed for change from baseline in evening PEF with FF100 mg OD ( Table 2 ). The rationale for the post-hoc sensitivity analysis and time-course figures for evening and morning PEF are provided in the Online Supplementary Material (Additional Methods and Fig. 2 ). Initial analysis of evening PEF found no significant difference between placebo and active therapy (Online Supplementary Material Table 2 ) meaning significance (regardless of p-value) could not be inferred for all subsequent efficacy comparisons because of the stepdown closed testing procedure employed. Morning PEF, percentage of symptom-free 24-h periods over the course of the study and AQLQþ12 at Weeks 12 and 24 were numerically improved by both active treatments compared with placebo (Table 2) . Least squares (LS) mean changes from baseline in the AQLQþ12 at week 24 were þ0.51, þ0.84 and þ0.68 units in the placebo, FF100 mg OD and FP250 mg BD arms, respectively.
Other outcomes
Improvements from baseline ACT score were observed for both active treatments compared with placebo at weeks 12 and 24 (Table 2) . LS mean changes from baseline were þ2.5 in the placebo arm, þ3.9 in the FF100 mg OD arm and þ3.6 in the FP250 mg BD arm. At baseline 13%, 14% and 12% of patients exhibited an ACT score of !20, indicating wellcontrolled asthma, in the placebo, FF100 mg OD and FP250 mg BD groups respectively. At Week 24 the corresponding percentages of patients with ACT score !20 were 48%, 55% and 51%, respectively. Twenty percent of patients withdrew due to lack of efficacy with placebo treatment. For FF100 mg OD and FP250 mg BD 13% and 12% of patients withdrew for the same reason, respectively. As illustrated in Online Supplementary Material Fig. 3 , both active treatments resulted in lower withdrawal rates compared with placebo.
Safety
A greater number of AEs, drug-related AEs and ontreatment AEs was observed with FF100 mg OD therapy compared with FP250 mg BD or placebo; no difference was apparent in the number of patients experiencing AEs leading to withdrawal (Table 3) . Drug-related AEs in !2 patients are listed in (Online Supplementary Material Table  3 ). On-treatment candidiasis (oral or oropharyngeal) occurred more frequently with FF100 mg OD (n Z 6) than with FP250 mg BD (n Z 2) or placebo (n Z 0). A total of nine on-treatment or post-treatment SAEs were reported in seven patients. Pyelonephritis and meningitis were reported by one patient each with placebo treatment. Abscess, Crohn's disease and epididymal cyst were reported by one patient each with FF100 mg OD treatment; one further patient receiving FF100 mg OD reported prostate cancer, Escherichia bacteraemia and pyelonephritis. Supraventricular tachycardia was reported by one patient receiving FP250 mg BD. The occurrence of Crohn's disease was the only SAE that led to withdrawal; none of the SAEs were considered to be related to the study drug. No deaths (asthma-related or otherwise) occurred during the study, nor did any asthma-related hospitalisations.
Severe on-treatment asthma exacerbations occurred in three (3%) patients receiving FF100 mg OD, two (2%) receiving FP250 mg BD and eight (7%) receiving placebo. All of these events were managed with systemic/oral corticosteroids. The least squares (LS) mean ratio to baseline at 
Discussion
The principal findings of this study were that (i) FF100 mg OD dosed in the evening over 24 weeks significantly improved lung function (pre-dose evening FEV 1 ) relative to placebo; (ii) the effect observed on lung function seen with FF100 mg OD was similar to that observed with FP250 mg BD; (iii) improvements in pre-dose evening FEV 1 with FF100 mg OD and FP250 mg BD were observed at the first time point assessed (Week 2), and were maintained throughout the study period; (iv) the percentage of 24-h periods free from the use of rescue medication was significantly improved with both FF100 mg OD and FP250 mg BD compared with placebo; and (v) a higher incidence of AEs was observed with FF100 mg OD compared to FP250 mg BD or placebo, though no difference was seen in the number of patients with AEs leading to withdrawal, and no SAEs were considered related to study medication.
Clinical decision-making in asthma is guided by the concept of asthma control [1] which is based on the frequency of symptoms and rescue use, the limitation of activities and pre-bronchodilator lung function; this approach has been prospectively assessed, with the majority of, but not all, patients studied achieving asthma control with an ICS or ICS/long-acting beta 2 agonist combination [18] . In the present study FF100 mg OD resulted in significant effects on both pre-dose evening FEV 1 and the percentage of rescue 24-h periods, compared with placebo; both of these endpoints are elemental components of the assessment of asthma control. That the effects seen on these endpoints with FF100 mg OD were similar to those achieved with FP250 mg BD suggests similar efficacy between the two therapies. Our study cohort was well matched across treatment groups and indicated that patients were using rescue medication most days at baseline and exhibited an FEV 1 that was approximately 72e73% of predicted, despite the use of a stable dose of ICS prior to study entry; i.e. at baseline the population was uncontrolled. This was also reflected by the majority of patients exhibiting an ACT score of 20 at baseline and a mean baseline ACT score of 15.4 in both active treatment arms and 15.9 in the placebo arm. Despite this level of uncontrolled asthma both FF100 mg OD and FP250 mg BD exhibited numerically greater effects than placebo on ACT, percentage of symptom-free 24-h periods and quality of life. However, it should be noted that while the minimally important difference (MID) for a change in ACT of 3 units [19] was not achieved versus placebo for either active therapy, the percentage of patents achieving well-controlled asthma (i.e. ACT !20) was greater in the ICS treatment groups than in those on placebo at the end of the 24-week treatment period, and the change from baseline did reach the MID with both active therapies but not with placebo. Equally, while the MID of 0.5 points [20] was not achieved for the AQLQþ12 versus placebo for either active therapy it was achieved versus baseline in both active treatment arms. The observation that the MID for the AQLQþ12 was also achieved in the placebo arm (þ0.51 units) may have been due to a healthy survivor effect, as more patients withdrew from the placebo arm than the FF100 mg OD or FP250 mg BD arms. These findings suggest that the effects of FF100 mg OD and FP250 mg BD on lung function, rescue use and symptom-free 24-h periods translated to a trend for improvement in the perception of symptoms and quality of life, albeit one that was not clinically important relative to placebo. Although statistical inference cannot be drawn from these comparisons it is apparent that the overall trend for effect suggests that FF100 mg OD has a positive effect on all of the key criteria related to the modern management of asthma. The findings with the active control (FP250 mg BD) suggest the study population was responding as expected to an established ICS; that the magnitude of the differences observed between FF100 mg OD and placebo, and FP250 mg OD and placebo were similar suggests the two ICS treatments had similar therapeutic effects.
The 100 mg dose of FF has previously been shown to improve pre-dose evening FEV 1 relative to placebo in asthma patients uncontrolled by a SABA alone [8] or uncontrolled on a low-dose ICS [9] over a period of 8 weeks. This improvement, though numerically lower in our study compared with the prior studies [8, 9] was still statistically significant and was maintained for the 6-month duration of the study. The lower magnitude of effect observed in the present study possibly reflects differences in study design, patient cohort as determined by inclusion criteria, or other differences. It is important to note that the difference for FP250 mg BD versus placebo in our study was also lower than Table 3 Summary of AEs (intention-to-treat population). that recorded in previous studies of FP in asthma [21] . Improvements in lung function with ICS treatment vary greatly in different patients and studies [21] , making it difficult to compare across studies. Furthermore, the overall level of asthma control in the Western world has increased over the last 20 years [22] ; these observations may also have contributed to the effects observed here with FF100 mg OD and FP250 mg BD. An important difference between the two active treatments, from a patients' perspective, is once-versus twicedaily dosing. Studies in a number of diseases, including cardiovascular disease [23] and hypertension [24] , have shown that adherence to medication is increased with an OD versus a BD treatment regimen. Similar findings have been reported in asthma [25, 26] . While an association between adherence and asthma control is known [27] the question remains as to whether OD dosing results in an increase in adherence in a 'real-world' setting, and whether any increase in adherence translates to an increase in asthma control.
Similar percentages (w40%) of patients reported AEs with placebo or FP250 mg BD treatment, while AEs with FF100 mg OD were reported by an additional w10% of patients. This increase in the total number of AEs reported with FF100 mg OD was primarily caused by a greater prevalence of rare events reported by one or two patients in the FF100 mg OD compared with the FP250 mg BD and placebo groups; i.e. no novel AE signal was observed with FF100 mg OD. A small but significant reduction in urinary cortisol was observed after 24 weeks of treatment with both FF100 mg OD and FP250 mg BD, an observation that has been reported in a 4-week study of FF100 mg/FF200 mg OD [7] and in a 12-week study of FF100 mg combined with the OD long-acting beta 2 agonist vilanterol [28] . However, these findings contrast with those of previous studies of FF100 mg OD assessed over 8-weeks [8, 9, 17] or 12-weeks [28] , or with FF100 mg/FF200 mg OD combined with vilanterol over 24 weeks [29, 30] or 52 weeks [31] . Serum cortisol is a more sensitive and reliable measure of cortisol secretion than urine sampling and in a 6-week study involving complete 24-h serum cortisol profiling (with 0e24 h weighted mean serum cortisol as the primary endpoint), FF/VI 100/25 mcg and FF/VI 200/25 mcg OD did not suppress serum cortisol (treatment ratio [95% CI] to placebo: 0.99 (0.87, 1.12) and 0.97 (0.86, 1.10), respectively) [32] . Corticosteroids, inhaled or otherwise, have the potential to induce adrenal suppression particularly when used at high doses, for a long duration, or by children [33e35]. The balance of evidence from studies of up to 52 weeks in duration, including the serum cortisol findings, suggests that clinical doses of FF (or FF/vilanterol) are unlikely to induce clinically relevant reductions in urinary cortisol, but further longer-term studies are warranted to assess any potential effect on cortisol levels in susceptible patients.
The current study included patients with asthma uncontrolled by their current ICS (who were therefore representative of the patient population in which FF100 mg OD may be used), was of sufficient duration to determine longer-term benefits and adverse events, and was both placebo-and active-controlled. The step-down closed statistical testing procedure employed represents both a strength and a limitation. This approach is a rigorous means of accounting for multiplicity of comparisons. In this study it meant, consequently, that no significance could be inferred for comparisons of morning and evening PEF, symptoms, quality of life and measures of asthma control. Another limitation of this study is that it was not powered or designed to analyse non-inferiority of FF100 mg OD and FP250 mg BD. Furthermore, even though many asthma patients are smokers [36] these individuals were excluded, to avoid any overlap with chronic obstructive pulmonary disease and chronic bronchitis, as is typical of most asthma clinical trials. This is relevant, as smoking is known to have a detrimental effect on the response to ICS in asthma patients [37, 38] and the efficacy and safety of FF in asthma patients who smoke remains to be determined. Finally, the <1 year study duration, and which only covered part of the Winter/Spring seasons when respiratory viruses are a major cause of asthmatic exacerbations, could be a possible limitation but exacerbation frequency was not a focus of this study (it was a safety endpoint).
In conclusion, this study shows that FF100 mg OD in asthma patients not controlled by their current ICS therapy significantly improves pre-dose evening FEV 1 and rescue use to an extent that is similar to that provided by FP250 mg BD, and is well tolerated.
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